Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer | Zendy

Ján Tkáč | Zendy; Veronika Gajdošová | Zendy; Štefánia Hrončeková | Zendy; Tomáš Bertók | Zendy; Michal Híreš | Zendy; Eduard Jáné | Zendy; Lenka Lorencová | Zendy; Peter Kasák | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer

Author(s) -

Ján Tkáč,

Veronika Gajdošová,

Štefánia Hrončeková,

Tomáš Bertók,

Michal Híreš,

Eduard Jáné,

Lenka Lorencová,

Peter Kasák

Publication year - 2019

Publication title -

interface focus

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.1

H-Index - 49

eISSN - 2042-8901

pISSN - 2042-8898

DOI - 10.1098/rsfs.2018.0077

Subject(s) - prostate cancer , prostate specific antigen , biomarker , medicine , cancer , prostate , oncology , antigen , immunology , biology , biochemistry

The initial part of this review details the controversy behind the use of a serological level of prostate-specific antigen (PSA) for the diagnostics of prostate cancer (PCa). Novel biomarkers are in demand for PCa diagnostics, outperforming traditional PSA tests. The review provides a detailed and comprehensive summary that PSA glycoprofiling can effectively solve this problem, thereby considerably reducing the number of unnecessary biopsies. In addition, PSA glycoprofiling can serve as a prognostic PCa biomarker to identify PCa patients with an aggressive form of PCa, avoiding unnecessary further treatments which are significantly life altering (incontinence or impotence).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research